Industry Group Letter Indicates Qualified Support For Bill To Allow Approval Of Generic Biotechnology Medications

Main Category: Pharma Industry / Biotech Industry
Article Date: 20 May 2008 - 7:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


The Biotechnology Industry Organization has issued a letter to Reps. Anna Eshoo (D-Calif.) and Joe Barton (R-Texas) to indicate qualified support for a bill (HR 5629) that they have introduced to allow FDA to approve generic biotech medications, CQ HealthBeat reports (McCarthy, CQ HealthBeat, 5/16).

The legislation would provide brand-name biotech companies with at least 12 years of market exclusivity before generic versions of their medications could reach the market. In addition, the bill would require clinical trials for generic versions of biotech medications, although FDA could waive the requirement. Under the bill, FDA could classify generic versions of biotech medications as interchangeable with brand-name versions at pharmacies, provided that the agency has developed guidance on the evidence required to prove interchangeability for a product class (Kaiser Daily Health Policy Report, 3/17).

In the letter, BIO President and CEO Jim Greenwood wrote that the group supports the legislation but seeks an increase in the period of market exclusivity from 12 to 14 years to encourage the development of new biotech medications. "Data exclusivity is absolutely necessary to preserve incentives for innovation," he wrote, adding, "A follow-on biologic -- by definition -- will not be the same as the innovative product, and thus, without data exclusivity, a follow-on manufacturer may produce a follow-on biologic that is 'similar enough' for regulatory approval purposes but different enough so as to avoid the innovator's patents" (CQ HealthBeat, 5/16).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Article adapted by Medical News Today from original press release.
Visit our pharma industry / biotech industry section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "Industry Group Letter Indicates Qualified Support For Bill To Allow Approval Of Generic Biotechnology Medications." Medical News Today. MediLexicon, Intl., 20 May. 2008. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/108049.php>

APA
Kaiser. (2008, May 20). "Industry Group Letter Indicates Qualified Support For Bill To Allow Approval Of Generic Biotechnology Medications." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/108049.php.

Please note: If no author information is provided, the source is cited instead.


Pharma Industry / Biotech Industry

Most Popular Articles



Follow Our Pharma Industry News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pharma Industry / Biotech Industry Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »